Mr. Hoitt brings more than two decades of successful commercial experience with an emphasis on rare diseases BEDFORD, Mass. / Apr 17, 2024 / Business Wire / Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced the appointment of Jason Hoitt as Chief Commercial Officer. Mr.... Read More

BEDFORD, Mass. / Apr 04, 2024 / Business Wire / Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that management will present at the 23rd Annual Needham Virtual Healthcare Conference on Wednesday, April 10, 2024, at 10:15 a.m. ET. A live webcast of the presentation,... Read More

BEDFORD, Mass. / Mar 27, 2024 / Business Wire / Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced the pricing of its upsized underwritten public offering of 5,555,557 shares of its common stock at a price to the public of $13.50 per share and, in lieu of common stock to... Read More

BEDFORD, Mass. / Mar 26, 2024 / Business Wire / Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced a proposed underwritten public offering in which it intends to offer and sell, subject to market and other conditions, up to $75 million of shares of its common stock. In... Read More

As of December 31, 2023, Company had $201.4 million in cash, cash equivalents, and marketable securities, anticipated to fund operations to the end of 2025 BEDFORD, Mass. / Mar 25, 2024 / Business Wire / Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today reported financial results... Read More

Phase 1/2a End of Study Data: 70mg doses demonstrated substantial and sustained reductions in convulsive seizure frequency on top of the best available anti-seizure medicines; Median reductions of 85% (n=10) at 3 months and 74% (n=9) at 6 months after last dose Open Label Extension Studies: Durable reductions in seizures and clinically meaningful improvements in multiple measures of cognition and behavior were maintained... Read More

BEDFORD, Mass. / Jan 17, 2024 / Business Wire / Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that, effective on January 16, 2024, the company granted stock options to purchase an aggregate of 13,300 shares of common stock to 2 new employees, as a material inducement... Read More

Data anticipated in Q1 2024 from studies of STK-001 for the treatment of Dravet syndrome End of Phase 1/2a study results and OLE data from patients receiving ongoing treatment; Analyses to include effects of STK-001 on seizure frequency, cognition and behavior Pending Q1 data, Company to request Phase 3 planning meetings with regulators As of September 30, 2023, Company had $214.7 million in cash, cash equivalents and... Read More

BEDFORD, Mass. / Jan 04, 2024 / Business Wire / Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that management will present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024, at 6:45 p.m. ET (3:45 p.m. PT). A live audio webcast of the... Read More

Data from clinical studies of STK-001 demonstrated clinical benefit for patients ages 2 to 18 years old, including reductions in seizures and improvements in cognition and behavior that support the potential for disease modification Analysis of 72 patients treated in STK-001 clinical trials suggests that higher STK-001 drug exposure in brain leads to greater seizure reductions Two-year data from the longest prospective... Read More

New data include 24-month results from the largest and longest prospective natural history study of children and adolescents with Dravet syndrome, which showed a lack of improvement despite treatment with available medicines Additional presentations include data that support advancement of STK-001 as potentially the first disease-modifying new medicine for Dravet syndrome, including data showing substantial reductions in... Read More

STK-001: Q1 2024 readout expected to include end of Phase 1/2a study results and longer-term data on the effects of repeat dosing on seizure frequency, cognition, and behavior from the ongoing open-label extension (OLE) studies STK-001: Company then plans to meet with regulators to discuss a Phase 3 study design; Update expected in 1H 2024 As of September 30, 2023, Company had $214.7 million in cash, cash equivalents and... Read More

BEDFORD, Mass. / Oct 17, 2023 / Business Wire / Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that, effective on October 16th, 2023, the company granted a stock option to purchase an aggregate of 32,800 shares of common stock to 1 new employee, as a material... Read More

BEDFORD, Mass. / Sep 21, 2023 / Business Wire / Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that management will participate in a panel presentation at the 2023 Cantor Global Healthcare Conference on Tuesday, September 26, 2023, at 9:55 a.m. ET. A live webcast of... Read More

Mr. Smith brings significant experience in the successful development and commercialization of medicines for rare genetic diseases BEDFORD, Mass. / Sep 20, 2023 / Business Wire / Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced the appointment of Ian Smith to its Board... Read More

Data from multiple ongoing clinical studies of STK-001 show reductions in convulsive seizure frequency and improvements in cognition and behavior in children and adolescents with Dravet syndrome Data support the potential for STK-001 to be the first disease-modifying treatment for Dravet syndrome New pharmacokinetic (PK) modeling of clinical data from ongoing studies demonstrate that higher STK-001 drug exposures in brain... Read More

STK-001: Additional data from patients treated with single and multiple doses (70mg) along with data from open-label extension studies (30mg, 45mg) anticipated in Q1 2024 STK-001: Company plans to share an update on Phase 3 planning in 1H 2024 STK-002: Company received authorization to initiate a Phase 1 study in the UK for the treatment of Autosomal Dominant Optic Atrophy (ADOA) As of June 30, 2023, Company had $231.4... Read More

BEDFORD, Mass. / Aug 02, 2023 / Business Wire / Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that management will present at the Canaccord Genuity 43rd Annual Growth Conference on Wednesday, August 9, 2023, at 4:30 p.m. ET. A live webcast of the presentation, which... Read More

Totality of data from these ongoing studies suggest clinical benefit for patients ages 2 to 18 years old, including reductions in seizures and improvements in cognition and behavior that support the potential for disease modification Phase 1/2a ADMIRAL Study Data STK-001 (70mg): Patients treated with 2 or 3 initial doses experienced substantial and sustained reductions in convulsive seizure frequency; Median reductions at 3... Read More

BEDFORD, Mass. / Jul 21, 2023 / Business Wire / Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that management will hold a webinar and conference call for analysts and investors at 8:00 a.m. Eastern Time on Tuesday, July 25, 2023, to present new data from the two... Read More

BEDFORD, Mass. / Jun 16, 2023 / Business Wire / Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that, effective on June 15, 2023, the company granted stock options to purchase an aggregate of 26,900 shares of common stock to 2 new employees, as a material inducement to... Read More

Company on-track to report new data from the ongoing Phase 1/2a clinical studies of STK-001 in children and adolescents with Dravet syndrome in mid-2023 Data readout will focus on safety and seizure frequency results for up to 16 patients who received three doses of 45mg of STK-001 Company plans to initiate a pivotal study in 2024, pending additional data from the Phase 1/2a studies Company received authorization to initiate... Read More

BEDFORD, Mass. / May 03, 2023 / Business Wire / Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that management will present at the BofA Securities Health Care Conference on Thursday, May 11, 2023, at 11:00 a.m. ET. (8:00 a.m. PT) A live webcast of the presentation,... Read More

Company advancing second TANGO ASO into the clinic STK-002 has the potential to be the first disease-modifying therapy to address the root cause of ADOA, the most common inherited optic nerve disorder BEDFORD, Mass. / Apr 25, 2023 / Business Wire / Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based... Read More

BEDFORD, Mass. / Mar 15, 2023 / Business Wire / Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that the FDA will allow the administration of a higher single dose of STK-001 (70mg) in its ongoing Phase 1/2a MONARCH study of children and adolescents with Dravet syndrome.... Read More

BEDFORD, Mass. / Mar 06, 2023 / Business Wire / Stoke Therapeutics, Inc. ( Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today reported financial results for the full year ended December 31, 2022 and provided business updates. “In 2022 we continued to advance the first potential new medicine to treat the... Read More

BEDFORD, Mass. / Feb 27, 2023 / Business Wire / Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that management will be participating at the following upcoming investor conferences: Cowen 43rd Annual Health Care Conference Date: Monday, March 6, 2023 Time: 12:50 p.m. ET... Read More

BEDFORD, Mass. / Feb 07, 2023 / Business Wire / Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that management will present at the virtual SVB Securities Global Biopharma Conference on Tuesday, February 14, 2023, at 4:20 p.m. ET. A live webcast of the presentation,... Read More

Additional safety and seizure frequency data from patients treated with multiple doses of STK-001 (45mg) anticipated in mid-2023 Data from the highest dose cohort (70mg) anticipated in the second half of 2023 Company expects to complete Phase 1/2a in 2023 in order to initiate a Phase 3 program in 2024 As of September 30, 2022, Company had $252.2 million in cash, cash equivalents, marketable securities, and restricted cash,... Read More

Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that management will present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023, at 2:15 p.m. ET (11:15 a.m. PT). A live audio webcast of the presentation will be available on the Investors &... Read More